Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors
HIV Infections

About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Drug Therapy, Combination, HIV Protease Inhibitors, Ritonavir, Indinavir, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Viral Load
Eligibility Criteria
Inclusion Criteria You may be eligible for this study if you: Are HIV-positive. Have a viral load (level of HIV in the blood) of 2500 copies/ml or greater within 45 days of study entry. Have a CD4 cell count of 100 cells/mm3 or greater within 45 days of study entry. Have been on an anti-HIV drug regimen containing a protease inhibitor for at least 16 weeks and initially did well on this treatment (your viral load decreased significantly) but later experienced treatment failure on this drug combination (your viral load increased significantly). Experienced treatment failure within 24 weeks of study entry. Are 18 years of age or older. Agree to use effective barrier methods of birth control (such as condoms) during the study. Exclusion Criteria You will not be eligible for this study if you: Are allergic to ritonavir or indinavir. Have hepatitis. Have an abnormal chest x-ray or abnormal liver function tests. Have taken 2 protease inhibitors at the same time for 7 or more days. Have taken non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the 2 weeks before study entry. Have a medical condition that might make it unsafe for you to take the study drugs. Have experienced resistance to NRTIs and no new NRTI therapy is possible. Have taken certain medications. Abuse alcohol or drugs. Are pregnant or breast-feeding.
Sites / Locations
- LAC / USC Med Ctr / Infectious Diseases
- Univ of Miami School of Medicine
- Northwestern Univ / Div of Infect Diseases
- Chase Braxton Health Service
- Beth Israel Deaconess Med Ctr
- Albany Med College
- Univ of North Carolina / Infectious Disease Division
- The Research and Education Group